Abstract
Background: Despite the traditional focus being adverse drug reactions (ADRs), pharmacovigilance centres have recently been identified as a potentially rich and important source of medication error data.
Objective: To identify medication errors in the New Zealand Pharmacovigilance database (Centre for Adverse Reactions Monitoring [CARM]), and to describe the frequency and characteristics of these events.
Methods: A retrospective analysis of the CARM pharmacovigilance database operated by the New Zealand Pharmacovigilance Centre was undertaken for the year 1 January–31 December 2007. All reports, excluding those relating to vaccines, clinical trials and pharmaceutical company reports, underwent a preventability assessment using predetermined criteria. Those events deemed preventable were subsequently classified to identify the degree of patient harm, type of error, stage of medication use process where the error occurred and origin of the error.
Results: A total of 1412 reports met the inclusion criteria and were reviewed, of which 4.3% (61/1412) were deemed preventable. Not all errors resulted in patient harm: 29.5% (18/61) were ‘no harm’ errors but 65.5% (40/61) of errors were deemed to have been associated with some degree of patient harm (preventable adverse drug events [ADEs]). For 5.0% (3/61) of events, the degree of patient harm was unable to be determined as the patient outcome was unknown. The majority of preventable ADEs (62.5% [25/40]) occurred in adults aged 65 years and older. The medication classes most involved in preventable ADEs were antibacterials for systemic use and anti-inflammatory agents, with gastrointestinal and respiratory system disorders the most common adverse events reported. For both preventable ADEs and ‘no harm’ events, most errors were incorrect dose and drug therapy monitoring problems consisting of failures in detection of significant drug interactions, past allergies or lack of necessary clinical monitoring. Preventable events were mostly related to the prescribing and administration stages of the medication use process, with the majority of errors 82.0% (50/61) deemed to have originated in the community setting.
Conclusions: The CARM pharmacovigilance database includes medication errors, many of which were found to originate in the community setting and reported as ADRs. Error-prone situations were able to be identified, providing greater opportunity to improve patient safety. However, to enhance detection of medication errors by pharmacovigilance centres, reports should be prospectively reviewed for preventability and the reporting form revised to facilitate capture of important information that will provide meaningful insight into the nature of the underlying systems defects that caused the error.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Leape LL, Brennan TA, Laird N, et al. The nature of adverse events in hospitalized patients: results of the Harvard Medical Practice Study II. N Engl J Med 1991 Feb 7; 324(6): 377–84
Wilson RM, Runciman WB, Gibberd RW, et al. The Quality in Australian Health Care Study. Med J Aust 1995; 163(9): 458–71
Bates DW, Leape LL, Petrycki S. Incidence and prevent-ability of adverse drug events in hospitalized adults. J Gen Intern Med 1993; 8(6): 289–94
Davis P, Lay-Yee R, Briant R, et al. Adverse events in New Zealand public hospitals: principal findings from a national survey. Occasional paper no. 3. Wellington: Ministry of Health [online]. Available from URL: http://www.moh.govt.nz/moh.nsf/pagesmh/1240?Open [Accessed 2010 Sep 28]
Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. Adverse Drug Events Prevention Study Group. JAMA 1997; 277(4): 307–11
Classen DC, Pestotnik SL, Evans RS, et al. Adverse drug events in hospitalized patients: excess length of stay, extra costs, and attributable mortality. JAMA 1997 Jan 22–29; 277(4): 301–6
Briant R, Ali W, Lay-Yee R, et al. Representative case series from public hospital admissions 1998:I. Drug and related therapeutic adverse events. N Z Med J 2004 Jan 30; 117(1188): U747 [online]. Available from URL: http://www.nzma.org.nz/journal/117-1188/747/content.pdf [Accessed 2010 Oct 11]
Phillips DP, Christenfeld N, Glynn LM. Increase in US medication-error deaths between 1983 and 1993. Lancet 1998 Feb 28; 351(9103): 643–4
Bates DW, Boyle DL, Vander Vliet MB, et al. Relationship between medication errors and adverse drug events. J Gen Intern Med 1995; 10(4): 199–205
Bates DW, Cullen DJ, Laird N, et al. Incidence of adverse drug events and potential adverse drug events: Implications for prevention. JAMA 1995; 274(1): 29–34
WHO Collaborating Center for Patient Safety Solutions. Nine life-saving patient safety solutions. Jt Comm J Qual Patient Saf 2007 Jul; 33(7): 427–62
Bates DW, Larizgoitia I, Prasopa-Plaizier N, et al. Global priorities for patient safety research. BMJ 2009; 338: 1242–4
McBride WG. Thalidomide and congenital abnormalities. Lancet 1961; II: 1358 [online]. Available from URL: http://www.jameslindlibrary.org/illustrating/records/thalidomide-and-congenital-abnormalities/whole_articles [Accessed 2010 Sep 28]
Uppsala Monitoring Centre (UMC). WHO Programme for International Drug Monitoring [online]. Available from URL: http://www.who-umc.org/DynPage.aspx?id=13140&mn=1514 [Accessed 2010 Jan 12]
Alj L, Touzani MDW, Benkirane R, et al. Detecting medication errors in pharmacovigilance database: capacities and limits. Int J Risk Saf Med 2007; 19(4): 187–94
Jonville-Bera AP, Saissi H, Bensouda-Grimaldi L, et al. Avoidability of adverse drug reactions spontaneously reported to a French regional drug monitoring centre. Drug Saf 2009; 32(5): 429–40
WHO. Patient safety: extending the scope of pharmacovigilance centres. WHO Pharmaceuticals Newsletter No. 6. Geneva: WHO, 2007
Bencheikh RS, Benabdallah G. Medication errors: pharmacovigilance centres in detection and prevention. Br J Clin Pharmacol 2009 Jun; 67(6): 687–90
Benkirane RR, Abouqal R, Haimeur CC, et al. Incidence of adverse drug events and medication errors in intensive care units: a prospective multicenter study. J Patient Saf 2009 Mar; 5(1): 16–22
Kunac D, Harrison-Woolrych M, Tatley M. Pharmacovigilance in New Zealand: the role of the New Zealand Pharmacovigilance Centre in facilitating safer medicines use. N Z Med J 2008; 121(1283): 76–89
Edwards IR, Biriell C. Harmonisation in pharmacovigilance. Drug Saf 1994 Feb; 10(2): 93–102
ICH Steering Committee. ICH harmonised tripartite guideline. Clinical safety data management: definitions and standards for expedited reporting [online]. Available from URL: http://www.ich.org/LOB/media/MEDIA436.pdf [Accessed 2009 Sep 16]
WHO Collaborating Centre for Drugs Statistics Methodology. Guidelines for ATC classification and DDD assignment [online]. Available from URL: http://www.whocc.no/atc_ddd_index/ [Accessed 2010 Sep 28]
Schumock GT, Thornton JP. Focusing on the preventability of adverse drug reactions. Hosp Pharm 1992; 27(6): 538
Dubois RW, Brook RH. Preventable deaths: who, how often, and why? Ann Intern Med 1988; 109(7): 582–9
Kunac DL, Reith DM, Kennedy J, et al. Inter-and intra-rater reliability for classification of medication related events in paediatric inpatients. Qual Saf Health Care 2006 Jun; 15(3): 196–201
Forrey RA, Pedersen CA, Schneider PJ. Interrater agreement with a standard scheme for classifying medication errors. Am J Health Syst Pharm 2007 Jan 15; 64(2): 175–81
NCC MERP. NCC MERP taxonomy of medication errors [online]. Available from URL: http://www.nccmerp.org/aboutMedErrors.html [Accessed 2009 Sep 12]
Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel of experts. Arch Intern Med 2003 Dec 8–22; 163(22): 2716–24
Morimoto T, Gandhi TK, Seger AC, et al. Adverse drug events and medication errors: detection and classification methods. Qual Saf Health Care 2004 Aug; 13(4): 306–14
Kozer E, Scolnik D, Jarvis AD, et al. The effect of detection approaches on the reported incidence of tenfold errors. Drug Saf 2006; 29(2): 169–74
Cullen DJ, Bates DW, Small SD, et al. The incident reporting system does not detect adverse drug events: a problem for quality improvement. Jt Comm J Qual Improv 1995; 21(10): 541–8
Kunac D, Kennedy J, Austin NC, et al. Incidence, preventability and impact of adverse drug events (ADEs) and potential ADEs in hospitalized children in New Zealand. Pediatr Drugs 2009; 11(2): 153–60
McDonnell PJ, Jacobs MR. Hospital admissions resulting from preventable adverse drug reactions. Ann Pharmacother2002 Sep; 36(9): 1331–6
Kaushal R, Bates DW, Landrigan C, et al. Medication errors and adverse drug events in pediatric inpatients. JAMA 2001; 285(16): 2114–20
Kunac DL, Reith DM. Preventable medication-related events in hospitalised children in New Zealand. N Z Med J 2008; 121(1272): 17–32
Hanlon JT, Schmader KE, Koronkowski MJ, et al. Adverse drug events in high risk older outpatients. J Am Geriatr Soc 1997 Aug; 45(8): 945–8
Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29(5): 385–96
Aronson JK, Ferner RE. Preventability of drug-related harms —part II: proposed criteria, based on frameworks that classify adverse drug reactions. Drug Saf 2010; 33(11): 995–1002
Acknowledgements
We acknowledge the invaluable contributions of our New Zealand Pharmacovigilance Centre colleagues, Dr Ruth Savage, who, along with Dr Michael Tatley, was involved in event assessment, and Janelle Ashton for assistance with data extraction. We also thank Dr Joanne Hart (Medsafe) who offered thoughtful comments on drafts of this manuscript.
This study was supported by a grant awarded to the authors by the Department of Preventive and Social Medicine, University of Otago, Dunedin, New Zealand. The authors’ work was independent of the funders. The authors have no conflicts of interest to declare.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kunac, D.L., Tatley, M.V. Detecting Medication Errors in the New Zealand Pharmacovigilance Database. Drug-Safety 34, 59–71 (2011). https://doi.org/10.2165/11539290-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11539290-000000000-00000